The possibility of using biomarkers in children with juvenile arthritis to predict the status of their condition at 12 months of age has now been demonstrated. The long-term disease status at 12 months was accurately predicted only after treatment had been initiated, in newly diagnosed patients.
JIA is the most common childhood* chronic rheumatic disease, 2 affecting 16-150 children in every 100,000. As indicated by the name, the cause of JIA is largely unknown.
Diet, Nutrition and Supplements for Osteo-Arthritis and Rheumatoid Arthritis
Rheumatoid arthritis patients should consume a diet rich in natural antioxidant and anti-inflammatory nutrients and avoid foods like sugar, saturated fats, and trans fatty acids.
Advertisement
"By predicting disease progression in these young children we can better understand the course of the disease and how best to treat the individual," said lead author of the study Professor James Jarvis, from the Department of Paediatrics, University at Buffalo, Buffalo, New York.
Blood gene expression profiling has led to major advances in the field of rheumatology over the last decade but to date it has only been possible to predict therapeutic outcome at 6 months.
![Hip replacement]( "Hip replacement")
Are you experiencing pain due to damaged hips? Travel abroad to get replacement surgery at affordable prices.
"The challenge was to test the feasibility of using these prognostic biomarkers from whole blood gene expression profiles in children with newly diagnosed JIA to predict disease status at one year," explained Professor Jarvis. "Baseline expression profiles that could predict disease status at six months could not predict status at 12 months. However, using four month data (the earliest point at which samples were collected from children on treatment) we were able to determine strong predictive properties for disease status at 12 months. Thus, after children had initiated therapy longer term outcome was predictable," Professor Jarvis said.
In this study, researchers also discovered the appearance of different mechanisms of response in Rheumatoid Factor (RF) positive† and RF negative patients after four months of therapy, a finding that could explain the relative refractoriness of RF positive patients to otherwise effective therapies.
Whole blood expression profiles were studied from children enrolled in the TREAT study, an NIH‡-funded clinical trial comparing methotrexate (MTX) with MTX + etanercept in children with newly-diagnosed JIA. Gene expression profiles were examined to determine those genes whose expression levels best predicted outcome (active vs. inactive disease) at 12 months.
Researchers have described seven types of JIA, which are distinguished by their signs and symptoms, the number of joints affected, the results of laboratory tests, and the family history. 3 In general, symptoms include joint pain, swelling, tenderness and stiffness that last for more than six continuous weeks; the condition can also affect the eyes and lymph nodes.
Source: Eurekalert
Hip replacement
Are you experiencing pain due to damaged hips? Travel abroad to get replacement surgery at affordable prices.
Advertisement
"The challenge was to test the feasibility of using these prognostic biomarkers from whole blood gene expression profiles in children with newly diagnosed JIA to predict disease status at one year," explained Professor Jarvis. "Baseline expression profiles that could predict disease status at six months could not predict status at 12 months. However, using four month data (the earliest point at which samples were collected from children on treatment) we were able to determine strong predictive properties for disease status at 12 months. Thus, after children had initiated therapy longer term outcome was predictable," Professor Jarvis said.
In this study, researchers also discovered the appearance of different mechanisms of response in Rheumatoid Factor (RF) positive† and RF negative patients after four months of therapy, a finding that could explain the relative refractoriness of RF positive patients to otherwise effective therapies.
Whole blood expression profiles were studied from children enrolled in the TREAT study, an NIH‡-funded clinical trial comparing methotrexate (MTX) with MTX + etanercept in children with newly-diagnosed JIA. Gene expression profiles were examined to determine those genes whose expression levels best predicted outcome (active vs. inactive disease) at 12 months.
Researchers have described seven types of JIA, which are distinguished by their signs and symptoms, the number of joints affected, the results of laboratory tests, and the family history. 3 In general, symptoms include joint pain, swelling, tenderness and stiffness that last for more than six continuous weeks; the condition can also affect the eyes and lymph nodes.
Source: Eurekalert
Oligoarthritis
Most parents when told that their child has arthritis find it hard to believe it, as arthritis is regarded an adult's disease.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Malaria parasites sync their molecular rhythms with the internal 24-hour clocks of their hosts, said researchers.
A latest research suggests that the quality of a person's post-work recovery in the evening can impact their mood when they resume work the next day.
Researchers are working on new strategies and solutions for sleep apnea to ward off a range of health risks including cognitive decline.
The scientists discovered that when the stem cells in the hair follicle are made softer, they have a higher chance of growing hair.
A combinatorial therapy provided promising beneficial results among people with ischemic stroke.